Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation... Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500.
- Mechanism
- Curator reviewed
Ardeparin binds to antithrombin III, accelerating its activity in inactivating factor Xa and thrombin, thereby inhibiting thrombosis. Ardeparin also binds to heparin cofactor II, inhibiting thrombin. Ardeparin does not effect prothrombin time (PT) assays and may prolong activated partial thromboplastin time (APTT). Ardeparin has double the anti-factor Xa activity versus anti-factor IIa activity, compared to unfractionated heparin which has approximately equal anti-factor Xa activity and anti-factor IIa activity.
- Primary indication
- For prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.Curator reviewed
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Ardeparin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account